Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23121032 | 0.92 | CTPS1 (0.51) | CTPS1 | |
| SCHEMBL29566569 | 0.92 | CTPS1 (0.51) | CTPS1 | |
| SCHEMBL21392334 | 0.87 | CTPS1 (0.50) | CTPS1 | |
| SCHEMBL21392333 | 0.87 | CTPS1 (0.38) | CTPS1WNT3A | |
| SCHEMBL21392153 | 0.85 | CTPS1 (0.45) | CTPS1WNT3A | |
| SCHEMBL29086297 | 0.83 | CTPS1 (0.52) | CTPS1 | |
| SCHEMBL29489085 | 0.83 | CTPS1 (0.52) | CTPS1 | |
| SCHEMBL22924881 | 0.83 | CTPS1 (0.53) | CTPS1 | |
| SCHEMBL21392248 | 0.83 | CTPS1 (0.50) | CTPS1 | |
| SCHEMBL21392149 | 0.80 | TRPM8 (0.38) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230192673-A1 | Compounds | STEP PHARMA S.A.S. (FR) | 2023-06-22 | — | — | US | disclosed |
| US-20230020663-A1 | SULFONAMIDE INHIBITORS AS CTPS1 INHIBITORS | STEP PHARMA S.A.S. (FR) | 2023-01-19 | — | — | US | disclosed |
| US-20230002352-A1 | SULFONAMIDE DERIVATIVES AS CTPS1 INHIBITORS | STEP PHARMA S.A.S. (FR) | 2023-01-05 | — | — | US | disclosed |
| US-20210387965-A1 | Compounds | STEP PHARMA S.A.S. (FR) | 2021-12-16 | — | — | US | disclosed |
| US-20210024507-A1 | Compounds | STEP PHARMA S A S (FR) | 2021-01-28 | — | — | US | disclosed |
| WO-2020245665-A1 | N-(4-(5-CHLOROPYRIDIN-3-YL)PHENYL)-2-(2-(CYCLOPROPANESULFONAMIDO)PYRIMIDIN-4-YL) BUTANAMIDE DERIVATIVES AND RELATED COMPOUNDS AS HUMAN CTPS1 INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISEASES | STEP PHARMA S.A.S. (FR) | 2020-12-10 | — | — | WO | disclosed |
| WO-2019180244-A1 | AMINOPYRIMIDINE DERIVATIVES AS CTPS1 INHIBITORS | STEP PHARMA S.A.S. (FR) | 2019-09-26 | — | — | WO | disclosed |
| WO-2019179652-A1 | AMINOPYRIMIDINE DERIVATIVES AS CTPS1 INHIBITORS | STEP PHARMA S.A.S. (FR) | 2019-09-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230020663-A1 | SULFONAMIDE INHIBITORS AS CTPS1 INHIBITORS | CTPS1, CTPS2, TYMS | CTPS1 1/4885WNT3A 4334/4885 |
| US-20230002352-A1 | SULFONAMIDE DERIVATIVES AS CTPS1 INHIBITORS | CTPS1, CTPS2, TYMS | CTPS1 1/4885WNT3A 4216/4885 |
| US-20210024507-A1 | Compounds | CYP1A1, UGT1A1, CYP1A2 | CTPS1 2586/4885WNT3A 2261/4885 |
| US-20230192673-A1 | Compounds | CYP1A1, UGT1A1, CYP1A2 | CTPS1 2586/4885WNT3A 2261/4885 |
| US-20210387965-A1 | Compounds | CYP1A1, UGT1A1, CYP1B1 | CTPS1 2704/4885WNT3A 2583/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.